Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Curtin

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Cellular and Molecular Medicine|December 25, 2024
A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian CancersM Zanjirband, M H Nasr-Esfahani, N J Curtin, et al.
Biochimie|January 1, 1995
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapyR J Griffin, N J Curtin, D R Newell, et al.
British Journal of Cancer|December 17, 2009
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cellsN Johnson, J Bentley, L-Z Wang, et al.
British Journal of Cancer|October 1, 1995
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitorsS Boulton, L C Pemberton, J K Porteous, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
British Journal of Cancer|February 22, 2014
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedulesJ Murray, H Thomas, P Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
British Journal of Cancer|May 29, 2014
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samplesM J Patterson, R E Sutton, I Forrest, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Cellular and Molecular Medicine|December 25, 2024
A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian CancersM Zanjirband, M H Nasr-Esfahani, N J Curtin, et al.
Biochimie|January 1, 1995
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapyR J Griffin, N J Curtin, D R Newell, et al.
British Journal of Cancer|December 17, 2009
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cellsN Johnson, J Bentley, L-Z Wang, et al.
British Journal of Cancer|October 1, 1995
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitorsS Boulton, L C Pemberton, J K Porteous, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
British Journal of Cancer|February 22, 2014
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedulesJ Murray, H Thomas, P Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
British Journal of Cancer|May 29, 2014
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samplesM J Patterson, R E Sutton, I Forrest, et al.
Pageof 5